Cytodyn Inc
OTC:CYDY
Intrinsic Value
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CYDY.
Fundamental Analysis
Balance Sheet Decomposition
Cytodyn Inc
Current Assets | 10.8m |
Cash & Short-Term Investments | 2.5m |
Other Current Assets | 8.3m |
Non-Current Assets | 487k |
PP&E | 400k |
Other Non-Current Assets | 87k |
Current Liabilities | 119.8m |
Accounts Payable | 62.7m |
Accrued Liabilities | 22.6m |
Other Current Liabilities | 34.5m |
Non-Current Liabilities | 997k |
Long-Term Debt | 714k |
Other Non-Current Liabilities | 283k |
Earnings Waterfall
Cytodyn Inc
Revenue
|
0
USD
|
Cost of Revenue
|
-20.6m
USD
|
Gross Profit
|
-20.6m
USD
|
Operating Expenses
|
-19.9m
USD
|
Operating Income
|
-40.6m
USD
|
Other Expenses
|
-39.2m
USD
|
Net Income
|
-79.8m
USD
|
Free Cash Flow Analysis
Cytodyn Inc
What is Free Cash Flow?
CYDY Profitability Score
Profitability Due Diligence
Cytodyn Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Cytodyn Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
CYDY Solvency Score
Solvency Due Diligence
Cytodyn Inc's solvency score is 21/100. The higher the solvency score, the more solvent the company is.
Score
Cytodyn Inc's solvency score is 21/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CYDY Price Targets Summary
Cytodyn Inc
Ownership
CYDY Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CYDY Price
Cytodyn Inc
Average Annual Return | 114.3% |
Standard Deviation of Annual Returns | 280.91% |
Max Drawdown | -98% |
Market Capitalization | 155.1m USD |
Shares Outstanding | 986 060 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. The company is headquartered in Vancouver Washington, Washington and currently employs 24 full-time employees. The company went IPO on 2005-11-17. The CCR5 receptor is a protein located on the surface of various cells including white blood cells and cancer cells. The CCR5 receptor is also the co-receptor needed for certain strains of human immunodeficiency virus (HIV) to infect healthy T-cells. The firm also completed a Phase IIb/III investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients. The firm is also conducting a Phase II clinical trial with leronlimab in metastatic Triple Negative Breast Cancer (mTNBC), a Phase II basket trial in solid tumor cancers (22 different cancer indications), Phase II investigative trial for post-acute sequelae of SARS COV-2, also known as COVID-19 long haulers, and a Phase II clinical trial for nonalcoholic steatohepatitis (NASH).